Paper Details

  1. Home
  2. Paper Details

Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis.

Author: De HertoghGert, FeaganBrian G, FriedmanJoshua R, LiKatherine, MaranoColleen, Peyrin-BirouletLaurent, RubinDavid T, SandbornWilliam J, SandsBruce E, YangFeifei, ZhangHongyan

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Histologic improvement in patients with ulcerative colitis (UC) treated with ustekinumab was associated with clinical remission and lower disease activity scores. The combination of histologic and endoscopic improvement, referred to as histo-endoscopic mucosal healing, was associated with higher rates of clinical remission and corticosteroid-free remission.
Paper Details　
Original Abstract of the Article :
BACKGROUND & AIMS: Ustekinumab induces and maintains histologic improvement in patients with ulcerative colitis (UC). The clinical relevance of this endpoint alone, and in combination with endoscopic improvement, is unknown. METHODS: Histologic disease activity was evaluated in 2630 colonic biopsy ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1053/j.gastro.2020.08.037

データ提供：米国国立医学図書館（NLM）

Ustekinumab for Ulcerative Colitis: A Promising Treatment with a New Endoscopic Endpoint

Ulcerative colitis, a chronic inflammatory bowel disease, is a challenging condition that can leave patients feeling trapped in a desert of discomfort. This research explores the effectiveness of ustekinumab, a biologic drug, in treating ulcerative colitis (UC) by examining the association between histologic and endoscopic endpoints and the efficacy of treatment. The study analyzed data from patients with UC who were treated with ustekinumab in clinical trials, assessing the impact of ustekinumab on histologic and endoscopic measures of disease activity. The researchers aimed to determine whether a combined endpoint of histologic and endoscopic improvement could provide a more comprehensive assessment of treatment response.

A New Endoscopic Endpoint for Ulcerative Colitis Treatment

The study found that histologic improvement was significantly associated with clinical remission, lower disease activity scores, and greater improvement in disease activity. Moreover, the study introduced a new combined endpoint, called histo-endoscopic mucosal healing, which combines histologic and endoscopic improvement. They found that patients achieving histo-endoscopic mucosal healing after induction therapy had higher rates of clinical remission and corticosteroid-free remission at the end of maintenance therapy compared to those with only histologic or endoscopic improvement.

Navigating Ulcerative Colitis Treatment with a New Compass

This research offers valuable insights into the use of ustekinumab for UC treatment, highlighting the importance of a combined histologic and endoscopic assessment for a more comprehensive understanding of treatment response. The study suggests that histo-endoscopic mucosal healing may be a more accurate predictor of long-term outcomes compared to individual histologic or endoscopic endpoints. If you're living with UC, it's crucial to discuss the latest treatment options with your doctor, including the potential benefits of ustekinumab and the importance of a comprehensive evaluation of treatment response.

Dr.Camel's Conclusion

The desert of ulcerative colitis can be challenging to navigate, but this research offers a new compass. The introduction of histo-endoscopic mucosal healing as a combined endpoint provides a more comprehensive assessment of treatment response and could lead to more effective and personalized treatment strategies for patients.

Date :
  1. Date Completed 2021-04-15
  2. Date Revised 2021-11-10
Further Info :

Pubmed ID

32853634

DOI: Digital Object Identifier

10.1053/j.gastro.2020.08.037

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.